Psoriatic Arthritis | Treatment Algorithms: Claims Data Analysis | US | 2017
The algorithms for treating psoriatic arthritis ( PsA ) are unique among rheumatic diseases because most PsA patients receive prior treatment by dermatologists for psoriasis, with many of the same therapies that are frequently used for PsA . Therefore, biologic and targeted synthetic DMARD s are more frequently used as early-line therapies after the diagnosis of PsA . Understanding the use of non- TNF inhibitors, namely, IL -12/23 inhibitors, IL -17 inhibitors, and PDE -4 inhibitors, is crucial for pharmaceutical companies to properly manage their brands in the PsA market. Claims data analysis provides an objective lens to see how physicians prescribe therapies and reveals real-world data on persistency and compliance of the PsA therapies.
Related Market Assessment Reports
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
